Table 1 Experimental vector vaccines against Mycoplasma hyopneumoniae tested in mice.
From: Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs
Antigen | Vector | Route | Nb of vaccinations | Humoral response | CMI responsea | Other/comments | References | |
|---|---|---|---|---|---|---|---|---|
Serum | BALFb | Â | ||||||
NrdF (R2) | Salmonella Typhimurium aroA SL3261 | Oral | 3 | No IgG, no IgA | IgA, no IgG | Â | Â | [75] |
P97 (R1) | Salmonella Typhimurium aroA CS332 (pro- and eukaryotic plasmid) | Oral | 2 | No | No | IFN-γ |  | [76] |
NrdF (R2) | Salmonella Typhimurium aroA CS332(pro- and eukaryotic plasmid) | oral | 2 | No | No | IFN-γ response (only with eukaryotic vector) |  | [77] |
P97 (R1) | Adenovirus | IM or IN | 2 | IM / IN: IgG IM: IgG2a/IgG1 = 4 IN: IgG2a/IgG1 = 1 | IM /IN: IgG, IgG1, IgG2a IN: IgA |  | Serum and BAL inhibited growth of M. hyopneumoniae | [78] |
P36 | Actinobacillus pleuropneumoniae SLW36 | IM | 2 | IgG | Â | Â | Â | [79] |
P97c | Adenovirus | IM | 2 | IgG, IgG1, IgG2a, IgG2b, IgG3 IgG2a/IgG1 ≈ 1 |  |  | P97c may act as immunopotentiator | [80] |
P97R1, P46 | Bacillus subtilis | IN | 2 | IgG | IgA | IFN-γ, Il-4 |  | [81] |